The Medicines and Healthcare Regulatory Agency (MHRA) said on Thursday that the risk associated with this type of blood clot is "very small" and that the public should continue to take up the vaccine when offered it.
The head of the European Union's drugs regulator says there is "no evidence" that would support restricting the use of AstraZeneca's COVID-19 vaccine in any population, as Germany and a handful of other European countries have done amid concerns over rare blood clots in people who got the shot.
In a statement today, the ministry said the decision to approve the vaccine produced by the Covax facility was based on the approval it received for emergency use from the World Health Organization (WHO) on Feb 15. Those figures included a "significant" number of the cases reported in Germany but not all, she said.
On Friday, the Dutch government also said it would be temporarily halting AstraZeneca jabs for people under 60, after it received five reports of blood clots with low blood plate counts following vaccinations.More news: Ontario will begin third provincial shutdown on Saturday, April 3, 2021
He emphasised the risk of Australians contracting COVID-19 was "far greater" than contracting the rare blood clotting disorder.
The man received his vaccine dose on March 22.
"I acknowledge that these reports lead to uncertainty and anxiety and we will continue to provide more information to you as soon as we have it available", Professor Kidd said.
A causal link with the AstraZeneca vaccine is yet to be established.More news: At least 48 dead after vehicle hits train, causes derailment in Taiwan
He said people should be particularly alert to severe and persistent headaches that occu between four and 20 days after the vaccination, which "are different to your usual pattern of headaches" and do not settle with paracetomol or other over-the-counter painkillers.
Out of the 18 million people vaccinated across the United Kingdom up to March 24, 30 had presented with the blood clots.
There were previously fears that Malaysia would discontinue its AstraZeneca programme following reports the vaccine caused blood clots.
The Australian Technical Advisory Group said there would be no change to the clinical guidance on the use of the AstraZeneca vaccine as a result of the EMA's findings. In late March, CSL Ltd began domestic production of 50 million doses.More news: Doug Ford to announce provincewide lockdown on Thursday